Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Blenrep (belantamab mafodotin) combinations approved by UK MHRA in relapsed/refractory multiple myeloma – GSK

Written by | 7 Jul 2025

GSK plc announced the authorisation of Blenrep by the Medicines and Healthcare products Regulatory Agency (MHRA). In the UK, Blenrep is approved for the treatment of adults with… read more.

FDA approves Susvimo (ranibizumab injection) for diabetic retinopathy – Roche

Written by | 6 Jul 2025

Roche announced that the FDA has approved Susvimo (ranibizumab injection) 100 mg/mL for the treatment of diabetic retinopathy (DR), a potentially blinding condition that affects almost 10 million… read more.

New AURORA 1 analysis: Lupkynis-based triple immunosuppressive therapy yields deep proteinuria reduction in lupus nephritis – Aurinia Pharma

Written by | 5 Jul 2025

Aurinia Pharmaceuticals Inc.  announced that a post-hoc analysis of the 52-week, Phase III AURORA 1 study presented at at LUPUS 2025, the 16th International Congress on SLE, showed… read more.

Merit Medical releases 12-Month efficacy results for the single-arm arteriovenous graft cohort of the WRAPSODY arteriovenous efficacy (WAVE) trial

Written by | 4 Jul 2025

Merit Medical Systems Inc. announced that the 12-month results from the single-arm cohort of the WAVE trial (NCT04540302) were presented at the annual Charing Cross Symposium held in… read more.

New study results reinforce Tagrisso as the backbone therapy for EGFR-mutated lung cancer across stages and settings – AstraZeneca

Written by | 3 Jul 2025

New study results presented at the European Lung Cancer Congress (ELCC) 2025 demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy and as the backbone for novel combinations,… read more.

CHMP recommends EU approval of Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer – Roche

Written by | 2 Jul 2025

Roche announced today that the EMA’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Itovebi (inavolisib), in combination with palbociclib (Ibrance) and… read more.

FDA grants approval for Tendyne, first-of-its-kind device to replace the mitral valve without open-heart surgery – Abbott

Written by | 1 Jul 2025

Abbott announced the FDA has approved the company’s Tendyne transcatheter mitral valve replacement (TMVR) system to treat people with mitral valve disease. This life-changing therapy is available for… read more.

Datroway (datopotamab deruxtecan) is approved in Japan as the first TROP-2 directed therapy for patients with HR positive, HER2 negative breast cancer – Daiichi Sankyo

Written by | 30 Jun 2025

Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been approved in Japan for the treatment of adult patients with hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or… read more.

NICE (UK) update for Paxlovid (nirmatrelvir plus ritonavir, sotrovimab and tocilizumab) for treating COVID-19 – Pfizer

Written by | 29 Jun 2025

NICE (UK) Nirmatrelvir plus ritonavir is recommended as an option for treating COVID‑19 in adults, only if they: i) do not need supplemental oxygen for COVID‑19 and, ii)… read more.

ACTION study describes inadequate care in the US of obesity – The Obesity Society

Written by | 28 Jun 2025

Few of the more than 90 million Americans with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment In… read more.

Soundstar Crystal ultrasound catheter launched in the US, redefining image clarity in 2D intracardiac imaging – Johnson & Johnson MedTech

Written by | 27 Jun 2025

Johnson & Johnson MedTech, announced the U.S. launch of the Soundstar Crystal Ultrasound Catheter for intracardiac echocardiography (ICE) imaging in cardiac ablation procedures. The device provides clearer, enhanced… read more.

SpringWorks Therapeutics receives positive CHMP Opinion for mirdametinib (Ezmekly) for the treatment of adult and pediatric patients with NF1-PN

Written by | 26 Jun 2025

SpringWorks Therapeutic Inc. announced the EMA’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.